Initial findings from a Phase 3 efficacy trial suggest Ionis Pharmaceuticals’ RNA-targeted treatment, given monthly or bimonthly, cut angioedema attacks more than placebo, the firm said Monday. The ...
Shares of Pharvaris PHVS rose nearly 22% on Wednesday after the company announced positive results from the phase III RAPIDe-3 study evaluating its lead pipeline drug deucrictibant in the hereditary ...
KalVista Pharmaceuticals, Inc. (KALV) had achieved a huge win announced just the other day on July 7th of 2025, whereby the FDA had approved its oral on-demand Hereditary Angioedema [HAE] plasma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results